1. Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762-769.

  2. Warren MF, Serby MJ, Roane DM. The effects of testosterone on cognition in elderly men: a review. CNS Spect. 2008;13:887-897. 

  3. Bassil N, Morley JE. Late-life onset hypogonadism: a review. Clin Geriatr Med. 2010;26:197-222. 

  4. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl. 2009;30:10-22.

  5. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl. 2009;30:23-32.

  6. Traish AM, Saad F, Feeley RJ, Guay A. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl. 2009;30:477-494.

  7. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:193-197. 

  8. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310-320.

  9. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late onset hypogonadism in males : ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol. 2009;55:121-130.

  10. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003;170(6 pt 1): 2348-2351.

  11. Lefkowitz GK, Taneja SS, Brown J, et al. Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol. 2002;168(4 pt 1):1415-1418.

  12. Coward RM, Simhan J, Carson CC 3rd. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int. 2009;103:1179-1183.

  13. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res. 2009;21:9-23.

  14. Marks LS, Hess DL, Dorey FJ, Macairan ML. Prostatic tissue testosterone and dihydrotestosterone in African-American and white men. Urology. 2006;68:337-341.

  15. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol. 2000;163:824-827.

  16. Chodak GW, Vogelzang NJ, Caplan RJ, et al. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA. 1991;265:618-621.

  17. Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169:1670-1675. 

  18. Isom-Batz G, Bianco FJ Jr, Kattan MW, et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005;173:1935-1937.

  19. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47:52-58.

  20. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-224.

  21. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192-1202.

  22. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74:505-508.

  23. Andriole GL, Humphrey P, Ray P, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol. 2004;172:915-919.

  24. Joly-Pharaboz MO, Soave MC, Nicolas B, et al. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. J Ster Biochem Mol Biol. 1995;55:67-76.

  25. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci. 1996;93:11802-11807.

  26. Morris MJ, Huang D, Kelly WK, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol. 2009;56:237-244.

  27. Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118-1126.

  28. Pierorazio PM, Ferrucci L, Kettermann A, et al. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 2010;105:824-829.

  29. Koo JM, Shim BS. Significance of serum testosterone prostate-specific antigen (PSA) elevation and prediction of prostate cancer in patients with PSA above 10 ng/ml. Korean J Urol. 2010;51:831-835.

  30. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172:920-922.

  31. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173:533-536.

  32. Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6:1165-1170.

  33. Sathyamoorthi K, Stein M, Mohammed O, et al. Testosterone replacement therapy in high risk patients following radical prostatectomy. J Urol. 2010; supp 183(4):e577 

  34. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109:536-541.

  35. Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int. 2009;103:62-64.

  36. Morgentaler A, Sweeney M, Bennett R, et al. PSA and follow up biopsy results in men who received testosterone therapy while on active surveillance for prostate cancer. J Urol. 2010 supp 183, abstract 1376. 

  37. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.

  38. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-492.

  39. Rhoden EL, Morgentaler A. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res. 2006;18:201-205.

  40. Cooper CS, Perry PJ, Sparks AE, et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol. 1998;159:441-443.

  41. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol. 1994;40:341-349.

HOW TO TAKE THE POST-TEST: To obtain CME credit, please click here after reading the article to take the post-test on